Cyclerion Therapeutics (NASDAQ:KRSA) Posts Earnings Results, Beats Expectations By $47.21 EPS

Posted by Stanley Muller on Nov 7th, 2026

Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($3.19) EPS for the quarter, topping analysts’ consensus estimates of ($50.40) by $47.21, Zacks reports.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ KRSA traded up $0.62 during trading hours on Friday, hitting $31.05. 65,598 shares of the company’s stock were exchanged, compared to its average volume of 154,760. The firm has a 50-day moving average of $32.16. Cyclerion Therapeutics has a 1-year low of $7.19 and a 1-year high of $59.36. The stock has a market cap of $1.41 billion, a PE ratio of -2.44 and a beta of 1.85.

Wall Street Analysts Forecast Growth

KRSA has been the subject of several recent analyst reports. Wedbush began coverage on Cyclerion Therapeutics in a research report on Monday, October 5th. They issued an “outperform” rating and a $44.00 target price for the company. Wall Street Zen upgraded shares of Cyclerion Therapeutics to a “sell” rating in a research report on Saturday, October 3rd. TD Cowen assumed coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They set a “buy” rating on the stock. UBS Group initiated coverage on Cyclerion Therapeutics in a research note on Friday, September 11th. They set a “buy” rating and a $55.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating and a $43.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Get Our Latest Research Report on Cyclerion Therapeutics

Cyclerion Therapeutics Company Profile

(Get Free Report)

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.